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Abstract 
11C-methionine (MET) has recently emerged as an accurate marker of tumor burden and disease 
activity in patients with multiple myeloma (MM). This dual-center study aimed at further 
corroboration of the superiority of MET as positron emission tomography (PET) tracer for staging 
and re-staging MM, as compared to 18F-2`-deoxy-2`-fluoro-D-glucose (FDG). 
78 patients with a history of solitary plasmacytoma (n=4), smoldering MM (SMM, n=5), and 
symptomatic MM (n=69) underwent both MET- and FDG-PET/computed tomography (CT) at the 
University Centers of Würzburg, Germany and Navarra, Spain. Scans were compared on a patient 
and on a lesion basis. Inter-reader agreement was also evaluated. In 2 patients, tumor biopsies for 
verification of discordant imaging results were available.  
MET-PET detected focal lesions (FL) in 59/78 subjects (75.6%), whereas FDG-PET/CT showed 
lesions in only 47 patients (60.3%; p<0.01), accordingly disease activity would have been missed in 
12 patients. Directed biopsies of discordant results confirmed MET-PET/CT results in both cases.  
MET depicted more FL in 44 patients (56.4%; p<0.01), whereas in two patients (2/78), FDG proved 
superior. In the remainder (41.0%, 32/78), both tracers yielded comparable results. Inter-reader 
agreement for MET was higher than for FDG (κ = 0.82 vs κ = 0.72). 
This study demonstrates higher sensitivity of MET in comparison to standard FDG to detect intra- 
and extramedullary MM including histologic evidence of FDG-negative, viable disease exclusively 
detectable by MET-PET/CT. MET holds the potential to replace FDG as functional imaging 
standard for staging and re-staging of MM. 
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Introduction 
Multiple myeloma (MM) accounts for 
approximately 1% of all cancers and around 10% of 
hematological malignancies [1, 2]. Although MM 
essentially remains incurable, overall survival has 
improved significantly over the last decade due to 
availability of various novel drugs and treatment 
options. The utility of molecular imaging using 
positron emission tomography (PET) with the 
radiolabelled glucose analog [18F]-2`-deoxy-2`-fluoro--









assessment has been demonstrated by several studies 
[3-7]. Moreover, the new International Myeloma 
Working Group response criteria include PET-based 
imaging in the evaluation of minimal residual disease 
[8]. However, glucose metabolism does not fully 
reflect the vast heterogeneity of the disease and does 
not allow for a refined understanding of tumor 
biology. Furthermore, diffuse bone marrow 
involvement and a rather low metabolic activity of 
myeloma can reduce sensitivity of FDG imaging [9]. 
Due to the rapid uptake and metabolic incorporation 
of radiolabelled amino acids into newly synthesized 
immunoglobulins [10], L-methyl-[11C]-methionine 
(MET) has emerged as a promising imaging agent 
[11]. We previously reported a significantly higher 
retention of MET in well-characterized myeloma cell 
lines and patient-derived CD138+-plasma cells and the 
feasibility of monitoring very early treatment 
response with MET in vitro and in vivo [12, 13]. 
Recently, in initial analyses MET outperformed FDG 
as a more accurate marker of tumor burden and 
disease activity [14-16]. This study was aimed to 
further determine the superiority of MET as PET 
radiotracer for functional imaging of MM at two 
different University centers. 
Materials and Methods 
This prospective study was approved by the 
local ethics committees of the University of Würzburg 
(212/13) and the University of Navarra (161/2015). 
All patients gave written informed consent to FDG- 
and MET- PET/computed tomography (CT) imaging 
according to the Declaration of Helsinki. MET was 
administered under the conditions of the 
pharmaceutical law (German Medicinal Products Act, 
AMG §13 2b; RD 1015/2009) according to the German 
and Spanish law and in accordance with the 
responsible regulator bodies (Regierung von 
Oberfranken; AEMPS). 
Subjects 
78 patients (45 males, 33 females, age 31-82 y, 
mean 59±10 y, 57 from Würzburg, 21 from Navarra) 
with a history of solitary plasmacytoma (n=4), 
smoldering MM (SMM, n=5), and overt MM (n=69) 
were prospectively enrolled. 17/78 patients were 
newly diagnosed while the remaining 61 subjects 
underwent imaging due to suspicion of disease 
relapse (n=38) or to rule out residual and/or new 
metabolically active disease (n=23, including 
plasmacytoma and SMM patients), respectively. At 
the time of PET/CT scanning, serum free 
immunoglobulin light chains (FLC; all patients) and 
the M component were recorded (n=70). Serum 
chemistry including lactate dehydrogenase (LDH, 
n=74), albumin (n=75), creatinine (all patients) and 
β2-microglobulin (β2m, n=68) were also available. 
Information on degree of bone marrow (BM) 
infiltration by myeloma cells based on iliac crest 
biopsy was simultaneously assessed in 54/78 (69.2%) 
patients. Additionally, interphase molecular 
cytogenetics based on fluorescence in situ 
hybridization (FISH) was available in 55/78 (70.5%) 
patients. Presence of del(17p), t(4;14), t(14;16), t(14;20) 
or chromosome 1 abnormalities were considered as 
elevated-risk, whereas all other karyotypes were 
classified as standard risk.  
A subgroup of this cohort (32 heavily pre-treated 
and 11 newly diagnosed patients, all from Würzburg) 
had previously been published [14]. 
PET/CT 
FDG and MET were synthesized in house with a 
16 MeV Cyclotron (Würzburg; GE PETtrace 6; GE 
Healthcare, Milwaukee, USA) and an 18 MeV 
Cyclotron (Navarra; Cyclone 18/9, IBA Radiopharma 
Solutions, Belgium). PET/CT was performed on a 
PET/CT scanner (Siemens Biograph mCT 64, 
Siemens, Knoxville, USA, both institutions) within a 
median interval of 1 day between scans (range, 0-21). 
FDG (mean, 303 ± 33 MBq) and MET (mean, 657 
± 147 MBq) were injected intravenously after at least 
4h fasting. CT scans were acquired after 60 (FDG) or 
20 min. (MET), respectively, using contrast-enhanced 
(FDG; depending on kidney function; dose 
modulation with a quality reference of 210 mAs 
[Würzburg]), non-contrast-enhanced (Care Dose 4D 
with a quality reference of 120 mAs [Navarra]) or 
low-dose spiral CT (80 mAs, 120 kV, a 512 × 512 
matrix, 5 mm slice thickness, increment of 30 mm/s, 
rotation time of 0.5 s, and pitch index of 0.8) including 
the skull to the proximal thighs. Consecutively, PET 
emission data were acquired in 3D-mode with a 200 × 
200 matrix with 2 min (Würzburg) or 3 min (Navarra) 
emission time per bed position. After decay and 
scatter correction, PET data were reconstructed 
iteratively with attenuation correction using a 
dedicated software (HD. PET, Siemens Esoft, 
Erlangen, Germany). 
Image analysis 
Criteria to define lesions as PET-positive by FDG 
were those previously proposed by Zamagni et al. 
[17], while for MET, positive lesions were visually 
determined as focally increased tracer retention 
compared to surrounding normal tissue or 
contralateral structures as previously described[14]. 
Presence and number of intra- and extramedullary 
(EMD) disease as well as location of lesions were 
recorded. Analysis both on a patient and a lesion basis 





was performed.  
In order to correlate tracer uptake with BM 
involvement, the number of intramedullary lesions 
detected by each tracer was compared to infiltration 
of malignant myeloma cells, as determined by bone 
marrow biopsy. 
Additionally, to assess the level of inter-reader 
agreement for presence or absence of disease on a 
patient basis, the nuclear medicine physicians from 
each center were blinded for clinical information and 
read the scans from the other hospital. 
PET-directed biopsies and histological 
assessment 
In two patients with discordant results between 
MET and FDG PET/CT, directed histopathological 
biopsies were performed in order to evaluate the 
specificity of the two PET radiolabels.  
Statistical analysis 
Statistical analyses were performed using PASW 
Statistics software (version 22.0; SPSS, Inc. Chicago, 
Illinois, USA). Quantitative values were expressed as 
mean ± standard deviation or median and range as 
appropriate. Comparisons of related metric 
measurements were performed using 
Wilcoxon-signed rank test. The Chi square- or Fisher 
exact test was conducted for comparison of frequency 
data between independent subgroups. For bivariate 
correlation analyses, Spearman or Pearson correlation 
coefficients were calculated. Levels of agreement 
between readers were measured using non-weighted 
κ statistics. κ values between 0.81 and 1.00 indicate 
very good agreement, 0.61 and 0.80 indicate good 
agreement, 0.41 and 0.60 indicate moderate 
agreement, and 0.21 to 0.4 indicate fair agreement 
[18]. All statistical tests were performed two-sided 
and a p-value < 0.05 was considered to indicate 
statistical significance. No correction for p-values was 
applied to adjust for multiple tests. 
Results 
69/78 (88.5%) of the patients investigated 
presented with symptomatic MM, while the 
remaining patients suffered from plasmacytoma (n=4, 
5.1%) or SMM (n=5, 6.4%). High-risk cytogenetics 
were present in 25/78 (32.1%) subjects. Information 
on the degree of iliac BM infiltration with MM plasma 
cells was available for 54/78 (69.2%) patients and 
ranged from 0 to 90% (median, 20% plasma cells). 
Serum FLC ranged from 0.69 to 28.983 mg/l (median, 
103.5) and M gradients from 0 to 58.9 g/dl (median, 
1.8) Patients´ characteristics are summarized in Table 
1 and Supplementary Table 1. 
 
Table 1. Patients´characteristics at the time of PET/CT evaluation 




Solitary plasmacytoma      
1 f 64 solitary plasmacytoma PD 0 9.0 (λ) 0 none 
2 f 48 solitary plasmacytoma PD n/a 4.4 3 none 
3 m 31 solitary plasmacytoma 9 0 1.8 0.5 RTx 
4 m 32 solitary plasmacytoma 14 n/a 1.7 0,5 CTx 
Smoldering Multiple Myeloma (SMM)      
5 m 68 SMM Ig G λ PD 3.69 8.7 (λ) n/a none 
6 m 74 SMM Ig G κ 43 21.1 791.5 n/a none 
7 m 44 SMM IgG λ 34 27.44 87.7 n/a none 
8 f 60 SMM Ig G κ 9 8.8 1.2 45 none 
9 f 65 SMM Ig G λ 125 1.81 1.7 1 none 
Multiple Myeloma (primary diagnosis)      
10 m 76 Ig G κ PD 3.4 4440 (κ) 40 none 
11 f 65 Ig A κ PD 0 233 (κ) 30 none 
12 m 54 Ig A κ PD 41.3 11.6 (κ) 70 none 
13 f 56 Ig A λ PD n/a 345 (λ) 25 none 
14 m 48 Ig G κ PD 58.9 48.0 (κ) n/a none 
15 f 74 Ig G λ PD 31.9 337 (λ) n/a none 
16 m 63 LC κ PD 1.9 14014 (κ) 70 none 
17 m 47 LC κ PD 0 904.9 (κ) 90 none 
18 m 62 LC λ PD 1.8 444.0 (λ) 15 none 
19 m 72 Ig G λ PD 35.4 5297 (λ) 90 none 
20 f 62 IgA κ PD 53.82 33.2 n/a none 
21 m 62 Ig G κ PD 12.33 259.7 n/a none 
22 f 61 IgG κ PD 2.47 158 20 none 
23 m 37 LC κ PD 1.9 291 8 none 
Multiple Myeloma (re-staging)      
24 f 65 Ig A κ 3 0 498 (κ) 50 CTx 
25 m 64 Ig G κ 4 51.1 293 (κ) 40 CTx 





26 f 60 Ig G κ 120 16.2 1237 (κ) n/a CTx, Auto-Tx 
27 m 60 Ig A λ 9 3.5 2525 (λ) 90 CTx, Auto-Tx 
28 m 82 Ig A κ 55 n/a 23.0 (κ) n/a CTx, 
29 m 67 Ig G λ 15 n/a 15.7 (κ) 5 CTx, Auto-Tx 
30 m 59 LC κ 7 3.4 n/a n/a RTx 
31 m 70 Ig G κ 103 23.2 8833 (κ) n/a CTx, Auto-Tx 
32 f 69 Ig G κ 10 26.4 687 (κ) n/a CTx, Auto-Tx 
33 f 63 LC κ 32 0 3079 (κ) n/a CTx, Auto-Tx 
34 f 64 Ig A κ 6 0 27,4 (κ) 0 CTx; Auto-Tx 
35 m 56 Ig A κ 32 44.7 0.5 (κ) 50 CTx, Auto-Tx 
36 f 62 Ig G κ 11 24.4 254.3 (κ) 15 CTx 
37 f 48 Ig A λ 63 6 177.7 (λ) 3 CTx, Auto-Tx 
31 m 51 Ig G κ 34 24.6 828.0 (κ) 60 CTx, Auto-Tx 
39 m 59 Ig G κ 37 0 5.0 (κ) 0 CTx, Auto-Tx 
40 m 59 Ig G κ 4 26.3 551.2 (κ) 40 CTx 
41 m 65 Ig G κ 89 10.4 37.8 (κ) n/a CTx, Auto-Tx 
42 f 65 Ig A κ 12 0 2387 (κ) 90 CTx, Auto-Tx 
43 f 39 Ig G λ 58 31.0 97.5 (λ) n/a CTx, Auto-Tx 
44 f 68 Ig G λ 31 29.8 1673 (λ) 35 CTx, Auto-Tx 
45 m 73 Ig G κ 72 4.7 25100 (κ) 70 CTx, Auto-Tx 
46 m 62 Ig G κ 199 13.0 14015 (κ) 20 CTx, Auto-Tx 
47 m 62 LC λ 47 0 240.8 (λ) 5 CTx, Auto-Tx 
48 f 53 LC κ 122 0 99.0 (κ) 15 CTx, Auto-Tx 
49 m 63 LC λ 6 0 12.4 (λ) 0 CTx 
50 f 63 Ig G κ 22 47.5 1907 (κ) 30 CTx, Auto-Tx 
51 m 63 Ig G κ 86 4.1 535.0 (κ) n/a CTx, Auto-Tx 
52 m 60 LC λ 22 0 124.2 (λ) 20 CTx, Auto-Tx 
53 f 63 LC λ 23 0 1876 (λ) 10 CTx, Auto-Tx 
54 f 49 Ig A λ 72 0 30.8 (λ) 0 CTx, Auto-Tx 
55 f 40 LC κ 39 0 50.0 (κ) n/a CTx, Auto-Tx 
56 f 46 Ig G λ 34 5.4 107.9 (λ) n/a CTx, Auto-Tx 
57 m 64 Ig G λ 64 0 1114 (λ) 0 CTx, Auto-Tx 
58 m 48 Ig G λ 10 0 16.1 (λ) 0 CTx 
59 m 62 Ig G κ 109 16.06 70.9 n/a CTx 
60 m 74 Ig A λ 83 0.88 28983 (λ) 50 CTx, Auto-Tx 
61 m 61 LC κ 23 0 2947 60 CTx 
62 f 62 Ig G κ 39 1.65 955 10 CTx, Auto-Tx 
63 f 66 LC λ 10 0 11.5 (λ) n/a CTx, Auto-Tx 
64 m 41 asecretory 19 0 n/a n/a CTx, Auto-Tx 
65 f 57 LC κ 64 1.77 5,1 60 CTx, Auto-Tx 
66 m 62 Ig G κ 122 0 1.3 0,5 CTx, Auto-Tx 
67 f 61 Ig G κ 124 1.7 12.3 27 CTx, Auto-Tx 
68 m 44 Ig G κ 3 0.9 0.7 4 CTx 
69 f 65 LC λ 29 1.5 2.8 6 CTx, Auto-Tx 
70 m 63 Ig G κ 44 1.8 137 20 CTx, Auto-Tx 
71 m 73 Ig G κ 106 0.71 24.9 40 CTx 
72 f 65 LC κ 47 0.18 87.4 19 CTx, Auto-Tx 
73 m 46 Ig G κ 6 0 0.4 5 CTx, Auto-Tx 
74 f 68 Ig G κ 46 0.25 3.5 n/a CTx, Auto-Tx 
75 m 51 Ig G κ 24 0.41 7.2 n/a CTx 
76 m 50 Ig G κ 32 n/a 28.6 4 CTx, RTx 
77 m 56 Ig D λ 40 n/a 123 n/a CTx, Auto-Tx 
78 f 48 Ig G κ 57 n/a 1 3 CTx, Auto-Tx 
m = male. f = female. Disease duration is given in months. PD = primary diagnosis. CTx = chemotherapy including novel agents. LC = light chain. RTx = radiotherapy. SMM 
= smoldering multiple myeloma. Auto-Tx = autologous stem cell transplantation. n/a = information not available. 
 
Patient-based analysis 
In PET/CT examinations with MET, MM lesions 
were detected in 59/78 patients (75.6%). In contrast, 
FDG did not identify any focal lesion in 31 patients 
(FDG-positive lesions in 47/78 patients, 60.3%; 
p<0.01). The 19 MET-negative patients corresponded 
to either cases in complete response (CR; n=13) or 
very good partial response (VGPR; n= 2) or cases with 
SMM (n=4). Of note, the remaining patient with SMM 
(patient #60) revealed increased MET uptake 
throughout the skeleton, whereas FDG-PET showed 
negative results (Figure 1). 
Additionally, MET identified extramedullary 
lesions in 15/78 patients (19.2%), whereas FDG 
identified 13/78 patients (p=n.s.) with EMD (16.7%). 
These extramedullary lesions corresponded to: soft 
tissue (9/78 [MET] vs. 7/78 [FDG]); lymph nodes 
(8/78 [MET] vs 7/78 [FDG]), lung (2/78 [MET] vs. 
2/78 [FDG] and liver (0/78 [MET] vs. 1/78 [FDG]). 
Regarding intramedullary MM, MET revealed 
involvement of the appendicular skeleton in 52/78 





patients (66.7%), whereas 14 cases were missed with 
FDG (FDG-positive lesions in 38/78 patients, 48.7%) 
(Supplementary Table 2).  
Inter-reader agreement 
Only one patient was not available for the 
inter-reader agreement evaluation due to technical 
reasons. Reproducibility of overall scan results was 
very good for MET scans with an agreement between 
readers in 72 of 77 scans. (κ = 0.82, 95% confidence 
interval [CI] 0.66-0.97). For FDG inter-reader 
agreement was good with consensus reached in 67 of 
77 examinations (κ = 0.72, 95% CI 0.56-0.88). 
Lesion-based analysis 
Imaging with MET identified more focal lesions 
than FDG in 44 patients (44/78, 56.4%, p<0.01), 
whereas FDG proved superior in only 2/78 (2.6%) 
cases (Figure 2). In the remaining 32/78 (41.0%) 
patients, an equal number of MM manifestations 
(identical lesions) was detected with both tracers.  
 
 
Figure 1. Display of a patient (patient #8) with Ig G κ SMM. Imaging with both tracers was performed on the same day. Whereas PET/CT with FDG did not depict 
hypermetabolic foci suspicious for active MM, MET demonstrated increased tracer uptake throughout the skeleton. Bone marrow biopsy revealed 45% clonal plasma 
cells. Blood tests showed an IgG κ M-spike of 8.6 g/dl, free light chain (FLC) κ levels of 1.22 mg/dl, and FLC λ levels of 0.13 mg/dl (ratio κ/λ= 9.38). Bence-Jones 
proteinuria was 191 mg/24 h-collected urine. The patient was diagnosed of high-risk smoldering MM and started treatment in a Spanish myeloma group clinical trial. 
After induction and consolidation treatment, she is in stringent complete response with MRD negativity as assessed by flow cytometry. 
 
Figure 2. Display of a patient (patient #57) with a history of Ig G λ MM. Imaging with both tracers was performed within 6 days. PET/CT with FDG depicted multiple 
hypermetabolic foci consistent with active MM which were partly missed by MET (transaxial slice of thoracic vertebra Th 7, arrows). 






Figure 3. Display of a patient (patient #60) with a history of Ig A λ MM. Imaging with both tracers depicted multiple hypermetabolic foci consistent with active MM. 
However, due to high physiologic uptake, extramedullary liver lesions were missed by MET-PET (arrows). 
 
MET-PET/CT detected ≥ 20 FL in 52 out of the 59 
positive patients (88.1%): 11/59 (18.6%) had ≥ 20 focal 
lesions detected, 8/59 patients (13.6%) ≥50 and 33/59 
patients (55.9%) ≥100 FL. The remaining 7/59 (11.9%) 
patients had less than 20 FL. With FDG, 21/47 (44.7%) 
subjects had <20 FL, 11/47 (23.4%) ≥20, 4/47 (8.5%) 
≥50 and 11/47 (23.4%) ≥100 FL.  
Interestingly, in 7/15 patients (46.7%) with EMD, 
MET detected lesions which were missed by FDG, 
whereas FDG outperformed MET in a single patient 
with hepatic EMD (Figure 3). In numbers, FDG 
detected a total of 44 EMD foci (soft tissue, n=20; 
lymph nodes, n=18; liver, n=4; lung, n=2), whereas 
MET depicted 72 lesions (p<0.01) in soft tissue (n=43), 
lymph nodes (n=24), and lungs (n=5). The lesions 
exclusively visualized by MET were found in soft 
tissue (n=23), lymph nodes (n=6), and lungs (n=3) 
(supplementary table 2). 
Correlation of tracer uptake with bone 
marrow involvement 
In the 54/78 (69.2%) patients in whom BM 
infiltration was histologically assessed by iliac crest 
biopsies or aspirates, the number of intramedullary 
lesions detected by PET imaging with either tracer 
correlated well with histologic plasma cell infiltration. 
Correlation with the histological findings was 
stronger for MET-PET (Spearman´s r=0.832) than for 
FDG-PET (Spearman´s r=0.635). 
PET-directed biopsies and histopathological 
assessment 
In order to confirm the specificity of MET-PET, 
directed histopathological biopsies were performed in 
two patients with discordant results between 
FDG-PET and MET-PET. In one case with FDG+ and 
MET- imaging (patient # 67, Figure 4), the guided 
biopsy did not show plasma cell infiltration whereas 
in the second case (MET+/FDG-, patient # 62, Figure 
5), infiltration of clonal plasma cells was confirmed. 
Accordingly, in both cases the biopsy results were 
concordant with the MET-PET findings. 
Discussion 
This study aimed at further validation of the 
radiolabelled amino acid MET for functional imaging 
of multiple myeloma. The superiority of MET over 
FDG was confirmed with concordant results in both 
University centers. Most interestingly, in two cases in 
which PET-guided biopsies were performed to clarify 
discordant PET imaging results the histopathological 
examination confirmed the MET based findings, with 
clonal plasma cells being present in the MET+/FDG- 
but being absent in the MET-/FDG+ lesion. This adds 
evidence that this radiolabel has higher sensitivity 
and specificity for myeloma lesions than FDG.  
In parallel with previously published data 
demonstrating higher sensitivity [14-16], MET 
provided more accurate information on the disease 





burden in the majority of patients and demonstrated 
higher inter-reader agreement. Based on PET-derived 
SUV, it also demonstrated a better correlation with 
histologic plasma cell infiltration as derived from iliac 
crest biopsy samples in comparison to FDG.  
Of note, MET demonstrated more myeloma 
lesions not only in intramedullary, but also in 
extramedullary disease. In almost half of the patients 
with EMD, exclusively MET+ lesions could be 
depicted. The biologically underlying implications are 
not yet fully understood. Further studies investigating 
samples from targeted biopsies (MET+/FDG+; 
MET-/FDG+; MET+/FDG-) are needed to derive a 
better estimate of the prognosis and refractoriness to 
treatment by the type of lesions displaying divergent 
MET and FDG uptake.  
 
 
Figure 4. Display of a patient (patient #71) with a history of Ig G κ MM after treatment initiation with lenalidomide and dexamethasone. The patient was referred for 
further evaluation of a painful, growing lesion in the proximal third of the right clavicle. The lesion demonstrated focal FDG uptake. In contrast, MET-PET was negative 
(arrows). Biopsy was performed and no tumor infiltration was demonstrated, consistent with a benign fracture. MET-PET additionally revealed partial response with 
inhomogeneous, focally increased tracer uptake of the axial as well as appendicular skeleton, whereas FDG-PET did not depict hypermetabolic foci suspicious for 
active MM in these locations. 
 
Figure 5. Display of a patient (patient #3) with a history of solitary plasmacytoma treated with radiotherapy. Imaging with both tracers was performed on the same 
day. Whereas PET/CT with FDG did not depict hypermetabolic foci suspicious for active MM, MET demonstrated focally increased tracer uptake in the left zygomatic 
bone (arrows). Biopsy confirmed monoclonal plasma cell infiltration. 





MET-PET was negative in most patients with 
MM in CR/VGPR and smoldering myeloma. 
Interestingly, a single patient with SMM presented 
with MET+/FDG- disease (Figure 2). Whereas it is too 
early to comment on the suitability of MET-PET for 
the identification of high-risk SMM patients, tracer 
uptake might reflect true active myeloma [19] and 
might be potentially of use to identify patients in 
conversion from asymptomatic disease stages to 
early, treatment demanding MM. While the value of 
blood markers and magnetic resonance imaging 
(MRI) for the identification of high-risk SMM were 
recently established and incorporated in the MM 
diagnostic criteria of the International Myeloma 
Working Group [20, 21], the role of PET/CT in SMM 
-despite first reports on the general suitability of FDG 
[22-24]- has not yet been comprehensively elucidated. 
A study on the diagnostic and prognostic value of 
FDG-, MET- and C-X-C motif chemokine receptor 4- 
(CXCR4-) directed PET [25-27] to determine the role of 
PET imaging in MM is currently ongoing in 
Würzburg. 
Additionally, another potential application of 
MET-PET might be considered in patients with 
(assumed) solitary plasmacytoma. Given the fact that 
a substantial proportion of patients develop MM 
within 2 years after radiotherapy of the solitary lesion 
[28], MET-PET performed at the initial presentation 
could contribute to detection of additional viable 
myeloma lesions and therefore, identify a patient 
subgroup benefitting from systemic therapy. Future 
research will clarify the role of MET-PET in this 
setting. 
As a potential drawback of the amino acid tracer, 
reduced sensitivity within the liver has been 
considered [29]. Indeed, in a single patient with 
hepatic MM involvement, MET did not detect the 
lesions due to the high physiologic uptake. However, 
given the broad availability of combined PET/CT 
imaging, this drawback should be overcome by the 
simultaneously acquired anatomic information. 
Future studies should address the prognostic value of 
MET in comparison to FDG and the performance of 
the tracer in early response assessment. A 
shortcoming of the present study is the limited 
number of patients with biopsy for verification of 
discordant FDG and MET imaging results. Although 
tumor biopsies from sites with discordant biologic 
behaviour (MET+/FDG-) have been carried out for the 
first time in this study, the underlying biological 
implications of these discrepant cases remain to be 
elucidated. Furthermore, another distinct pattern of 
myeloma lesions has been shown by receptor-directed 
PET targeting CXCR4 [26, 30, 31]. A current 
PET-guided biopsy project at our centers aims at a 
more elaborated analysis of biologically different 
myeloma lesions in order to gain further insight into 
MM heterogeneity. Additionally, a comparison of 
MET with other metabolic tracers like 11C-choline or 
11C-acetate is currently ongoing. 
Of note, the phenomenon of about 10% of 
FDG-PET “false-negative” patients due to low 
expression of hexokine-2 has been recently reported 
and might at least mechanistically explain the 
differences observed between the two PET tracers 
[32]. Since these patients cannot be monitored by 
FDG-PET, MET might overcome this limitation and 
aid in therapy monitoring in this relevant sub-group 
of patients. 
Overall, this study adds sustained evidence on 
the suitability of MET-PET for assessment of myeloma 
tumor burden. It indicates superiority over standard 
FDG-based imaging. Importantly we report the first 
evidence of histologically proven FDG-negative MM 
detectable by MET. Taken together, it can be 
hypothesized that MET-PET adds significant benefit 
to our diagnostic armamentarium in MM. Further 
clinical trials including a comprehensive evaluation of 
the prognostic and predictive value of this technology 
are clearly needed.  
Conclusion 
In conclusion, this study presents –for the first 
time- histologic proof of FDG-negative, viable MM 
detectable by MET-PET/CT. MET holds the potential 
to replace FDG as functional imaging standard for 
MM.  
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